Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Anaptysbio (ANAB) Change in Receivables (2016 - 2017)

Anaptysbio filings provide 2 years of Change in Receivables readings, the most recent being -$1.2 million for Q1 2017.

For the quarter ending Q1 2017, Change in Receivables fell 3400.0% year-over-year to -$1.2 million, compared with a TTM value of -$1.2 million through Dec 2017, down 122400.0%, and an annual FY2017 reading of -$1.2 million, down 122400.0% over the prior year.
Change in Receivables hit -$1.2 million in Q1 2017 for Anaptysbio, down from $365000.0 in the prior quarter.
The five-year high for Change in Receivables was $365000.0 in Q4 2016, with the low at -$1.2 million in Q1 2017.